Lower extremity artery disease (LEAD) is a marker of a more advanced atherosclerotic
process often affecting multiple vascular beds beyond the lower limbs, with a consequent …

The mortality effects and risk–benefit profile of low dose rivaroxaban (2.5 mg twice daily) in
patients with coronary heart disease are not completely understood. Five randomized …

Patients with coronary artery disease (CAD), peripheral artery disease (PAD), or both remain
at risk of cardiovascular events (including peripheral ischemic events), even when they …

Stable ischaemic heart disease is a frequent and very heterogeneous condition. Drug
therapy is important, in these patients, for improving their prognosis and controlling their …

Background: This study aims to explore the role of low-dose rivaroxaban (≤ 10 mg daily) for
the treatment of atherosclerotic cardiovascular disease (ASCVD). Methods: PubMed …

Background Long‐term antithrombotic strategies for patients with chronic coronary
syndrome with high‐risk factors represent an important treatment dilemma in clinical …

Aims Patients with coronary artery disease (CAD) and patients with peripheral artery
disease (PAD) are at risk for major adverse cardiovascular events (MACE) and major …

Abstract Purpose of Review Peripheral artery disease (PAD) affects an estimated 200 million
people worldwide and is associated with significant cardiovascular morbidity and mortality …

2 Arterioscler Thromb Vasc Biol April 2018 ticagrelor was superior to clopidogrel in> 18 000
patients with ACS (either STEMI or non-STEMI) undergoing PCI who were treated with …

Background and aim Despite optimal secondary preventive treatment, patients with stable
coronary artery disease (SCAD) remain at high risk of cardiovascular events. This …